Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteosarcoma as a second malignant neoplasm.

Merlin R Hamre1, Richard K Severson, Paul Chuba

  • 1Department of Pediatrics, Wayne State University, Detroit, MI, USA.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncommon Presentation of a Rib Osteochondroma Misdiagnosed as a Breast Lesion: A Case Report.

Case reports in orthopedics·2026
Same author

Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.

International journal of radiation oncology, biology, physics·2025
Same author

Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.

International journal of cancer·2025
Same author

A skeleton in a huff: insights in etiologies of osteosclerosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2024
Same author

Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Leukemia·2023
Same author

Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.

Human pathology·2023
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Dosimetric verification of every treatment plan: Do or not to do?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives? Optimizing PSQA in radiotherapy workflows through commissioning and standardized treatment planning with class solutions.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

Pre-treatment PSQA - Do we still need to measure and what are adequate alternatives?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same journal

How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
See all related articles

Secondary osteosarcomas, often linked to prior carcinomas in the elderly, show a 50% lower 5-year survival. This outcome may differ with modern treatments for this rare bone cancer.

Area of Science:

  • Oncology
  • Epidemiology
  • Cancer Research

Background:

  • Osteosarcoma is a rare primary bone cancer.
  • Secondary osteosarcomas arise following other malignancies or treatments.
  • Understanding differences between primary and secondary osteosarcomas is crucial for treatment and prognosis.

Purpose of the Study:

  • To compare the characteristics and outcomes of primary versus secondary osteosarcomas.
  • To analyze data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program.

Main Methods:

  • Utilized the SEER Cancer Incidence Public-Use Database (1973-96).
  • Identified 1,511 primary and 133 secondary osteosarcomas.
  • Employed logistic regression and survival analyses (Kaplan-Meier, proportional hazards).

Related Experiment Videos

Main Results:

  • Secondary osteosarcomas were more common in older adults (>40 years) and non-extremity sites.
  • Five-year overall survival was 50% lower for secondary osteosarcomas.
  • Associated primary malignancies included carcinomas, lymphomas, leukemias, and other sarcomas.

Conclusions:

  • Secondary osteosarcomas are associated with prior carcinomas, particularly in elderly patients.
  • A significant decrease in 5-year survival was observed for secondary osteosarcomas.
  • Current survival rates may be improved by contemporary, aggressive therapeutic approaches.